Abstract
The viral safety of virus-inactivated plasma products has been markedly enhanced by the improvement in tests for screening donations and by the improvement in techniques for manufacture of plasma derivatives including methods for virus inactivation. Nevertheless, there remains a weakness in removing inactivating heat-resistant non-enveloped viruses, such as parvovirus B19. Manufacturers' efforts should continue to be concentrated on this challenge.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
